With funding from the National Eye Institute, the team of researchers will focus on developing a broad-spectrum immunomodulatory eye drop for patients dealing with dry eye and ocular surface disease stemming from inflammatory and immune system disorders.
The bulk of a $25 million gift from the Henry L. Hillman Foundation will drive vision care research and development through The Eye and Ear Foundation and the University of Pittsburgh Departments of Ophthalmology and Otolaryngology.
According to a survey by the Larry A. Green Center, in collaboration with the Primary Care Collaborative (PCC) and 3rd Conversation, primary care offers assets, including experience and relationships with patients.
Gene therapies to mitigate the effects of mutations that cause blindness are undergoing rapid development. Investigators have found that novel gene vectors reduce the risks associated with these procedures.
Dr. Bath could be the first African-American woman inducted into the Hall. As the first African-American woman to receive a medical patent, for the laserphaco probe, and the first woman to lead a post-graduate training program in ophthalmology, her experience is extensive.
Findings from a new quality of life (QOL) assessment on thyroid eye disease (TED) indicate that the impact on patients extends well beyond its active phase and into the chronic phase.
The drop, formerly prescribed as Pazeo, joins Alcon’s over-the-counter ocular allergy portfolio to meet a variety of patient needs.
Applicants must submit an original essay focusing on how biologics are transforming regenerative medicine in eye care. The deadline to apply is March 12.
Biophytis will begin recruiting patients in France and Belgium for the second part of the COVA Study analyzing its leading drug candidate as a potential treatment for acute respiratory failure linked to COVID-19.
New World Medical relied on feedback from surgeons in the development of the device, which was registered with the FDA in October.
LumiThera has announced positive interim data in visual and ERG clinical outcomes in the ELECTROLIGHT pilot study in dry AMD patients.
To mark the 20th anniversary of its TECNIS IOLs, Johnson & Johnson Vision is launching the “See More” campaign to educate patients and physicians on what is possible with cataract surgery.
The session duration is 4 hours per week over the course of about 6 months, according to Jorge L. Alió, MD, PhD, FEBO, director of the course.
Rapid test allows healthcare professionals to make fast decisions at the point of care.
Investigators are studying the use of photobiomodulation in the treatment of dry age-related macular degeneration.
Following a successful Phase 2 study, a Phase 2/3 clinical trial for the compound is currently planned for mid-2021.
Investigators from the University of Pittsburgh and West Virginia University will collaborate on an international glaucoma laser study funded with a combined $15.2 million grant.
Paul S. Bernstein, MD, PhD, leads a team of University of Utah investigators that has developed a method for synthesizing large enough quantities of very-long-chain polyunsaturated fatty acids to evaluate their potential sight-preserving properties.
Bascom Palmer Eye Institute will hold its 18th annual meeting, titled Angiogenesis, Exudation, and Degeneration 2021, a virtual event set for February 12-13.
Fellows, residents from around the world show promise for future of retinal research.
The study focused the safety and tolerability of increasing doses of polihexanide eye drops in order to choose a dose that would be tested in a phase III clinical trial in patients with acanthamoeba keratitis.
Investigators at the Wilmer Eye Institute at the Johns Hopkins University School of Medicine conducting experiments in mouse tissues and human cells found that they may be able improve the success rate for regrowing nerve cells damaged by blinding diseases.
The Phase 1 clinical trial of EyePoint Pharmaceuticals Inc.’s EYP-1901 is underway. It is a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration.
Visus Therapeutics CEO Ben Bergo shares an update on the status of its lead product candidate for presbyopia treatment as well as what's in the company's pipeline for 2021.
The FDA has granted Fast Track designation to MeiraGTx's AAV-CNGA3 gene therapy product candidate for the treatment of achromatopsia (ACHM).
Ocular symptoms in COVID-19 patients may be more common than previously thought — with sore eyes a significant sign of disease.
In observance of International Holocaust Remembrance Day this January 27, John H. Merey, MD, may be the only Holocaust survivor still in the practice of ophthalmology.
The investigational therapy met all primary endpoints of absence of inflammation at both Day 8 and Day 15 for the treatment of pain and inflammation following cataract surgery.
Neurophth Therapeutics, Inc (Neurophth) and AAVnerGene Inc have announced the launch of a strategic partnership that will grant Neurophth global rights to mutually select adeno-associated virus (AAV) capsids for the creation of the next-generation ophthalmic gene therapy.
Bausch + Lomb has enrolled 599 participants in the first of two Phase 3 studies evaluating perfluorohexyloctane as a first-in-class investigational drug to treat the signs and symptoms of dry eye disease associated with meibomian gland dysfunction.
.png "Optometry Times"){kind=logo}
